Key facts
- This page summarizes Jonathan Young's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Dec 2021, 16:06.
Jonathan Young - 08 Dec 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- AKRO
- Reported as of
- 08 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Dec 2021, 16:06:26 UTC
- Prior SEC filing
- 05 Nov 2021
- Next SEC filing
- 11 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Young
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Young filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 10 Dec 2021.
Change
- Previous filing in this sequence was filed on 05 Nov 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKRO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +87,221
- Change %
- Price
- $0.000000
- Shares after
- 87,221
- Date
- 08 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 87,221
- Exercise price
- $21.10
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option shall vest and become exercisable in 48 equal monthly installments commencing on December 8, 2021.